{
  "id": "511a20f3df1ebcce7d00000c",
  "type": "list",
  "question": "Which are the most widely reported side-effects in the treatment of Crohn's disease?",
  "ideal_answer": "Leukopenia, paresthesia, psoriasis, alopecia and hemolysis are the most commonly reported side effects depending on the treatment. Severe adverse effects include myelosuppression, liver toxicity and hyperplasia, pancreatitis and pericarditis. The most severe but rare side-effects reported are progressive multifocal leukoencephalopathy (PML), serious infections, and lymphoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/20458240",
    "http://www.ncbi.nlm.nih.gov/pubmed/3069176",
    "http://www.ncbi.nlm.nih.gov/pubmed/30666",
    "http://www.ncbi.nlm.nih.gov/pubmed/21453886",
    "http://www.ncbi.nlm.nih.gov/pubmed/21254868",
    "http://www.ncbi.nlm.nih.gov/pubmed/18989561",
    "http://www.ncbi.nlm.nih.gov/pubmed/17628557",
    "http://www.ncbi.nlm.nih.gov/pubmed/11205659",
    "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
    "http://www.ncbi.nlm.nih.gov/pubmed/12603508",
    "http://www.ncbi.nlm.nih.gov/pubmed/17667053",
    "http://www.ncbi.nlm.nih.gov/pubmed/6139796",
    "http://www.ncbi.nlm.nih.gov/pubmed/9399771",
    "http://www.ncbi.nlm.nih.gov/pubmed/18469440",
    "http://www.ncbi.nlm.nih.gov/pubmed/10981226",
    "http://www.ncbi.nlm.nih.gov/pubmed/18788068",
    "http://www.ncbi.nlm.nih.gov/pubmed/20919963",
    "http://www.ncbi.nlm.nih.gov/pubmed/19420815",
    "http://www.ncbi.nlm.nih.gov/pubmed/9005529",
    "http://www.ncbi.nlm.nih.gov/pubmed/9097825",
    "http://www.ncbi.nlm.nih.gov/pubmed/7084615"
  ],
  "snippets": [
    {
      "text": "Different cutaneous side effects have been described for anti-TNF-\u03b1 therapy such as psoriasis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21453886",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Anti-TNF drug-induced alopecia is a less well-known side effect of this class of drugs.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "3 patients who developed scalp alopecia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21317611",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21254868",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "side effects appearing in about a fifth of the patients, including myelosuppression and liver toxicity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20919963",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Persistent corneal endothelial deposits associated with rifabutin therapy for Crohn's disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20458240",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "complained of alopecia 3 days after starting 6-mercaptopurine (6-MP) and then developed severe myelosuppression",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19420815",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Leucopoenia was the more frequent side effect observed, occurring in 36 (34%)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989561",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Nausea, vomit, although slight, occurred in 29 (27.4%)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989561",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Nodular regenerative hyperplasia as a side effect of azathioprine in a patient with Crohn's disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788068",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The whole blood count revealed a pancytopenia, hyperbilirubinemia and slightly elevated transaminases",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788068",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Analysis of the liver histology was highly suggestive of an azathioprine-related, nodular regenerative hyperplasia",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18788068",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "3 serious adverse events (SAEs) known to be associated with CD treatment (progressive multifocal leukoencephalopathy (PML), serious infections, and lymphoma)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17628557",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17667053",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A severe side effect is acute pancreatitis, which is specific for Crohn's disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18469440",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Recurrent myopericarditis in association with Crohn's disease",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12603508",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/11205659",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10981226",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Leukopenia and thrombocytopenia are observed mostly as a side effect of therapy, particularly with use of immunosuppressive drugs",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399771",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Immune thrombocytopenic purpura is rarely reported in association with inflammatory bowel disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9399771",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "resulted to watery stools, vomiting, and fever",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9097825",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Eosionophilia was present and the lymphocyte stimulation test with mesalazine was positive",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9097825",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Pericarditis as a side effect induced by sulfasalazine or 5-aminosalicylic acid",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9005529",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The commonest side-effect was hyperaesthesia, but one patient developed nephrotoxicity and one developed hepatotoxicity",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/3069176",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The only troublesome side effect is paresthesia, which apparently is dose-related and not progressive",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6139796",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The only major side effect observed was paresthesias. These occurred in 50% of the patients and developed in the patients at a mean of 6.5 mo after the onset of treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7084615",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Hemolysis is not a rare side-effect of sulfasalazine therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30666",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "17 of 40 (43%) patients with inflammatory bowel disease receiving sulfasalazine had evidence of hemolysis as detected by starch gel electrophoresis",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30666",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.disease-ontology.org/api/metadata/DOID:8577",
    "http://www.disease-ontology.org/api/metadata/DOID:8778"
  ],
  "exact_answer": "Leukopenia, paresthesia, psoriasis, alopecia, hemolysis, pancreatitis, liver toxicity, pericarditis"
}